Ma Shuai, Wang Fang, Liu Qingzhen, Geng Xiaoteng, Wang Zaibin, Yi Menglei, Jiang Fan, Zhang Dongtao, Cao Junzheng, Yan Xiuwei, Zhang Jiheng, Wang Nan, Zhang Heng, Peng Lulu, Liu Zhan, Hu Shaoshan, Tao Shengzhong
Department of Neurosurgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Cancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Front Pharmacol. 2023 Jun 7;14:1170240. doi: 10.3389/fphar.2023.1170240. eCollection 2023.
Necroptosis is a programmed form of necrotic cell death that serves as a host gatekeeper for defense against invasion by certain pathogens. Previous studies have uncovered the essential role of necroptosis in tumor progression and implied the potential for novel therapies targeting necroptosis. However, no comprehensive analysis of multi-omics data has been conducted to better understand the relationship between necroptosis and tumor. We developed the necroptosis index (NI) to uncover the effect of necroptosis in most cancers. NI not only correlated with clinical characteristics of multiple tumors, but also could influence drug sensitivity in glioma. Based on necroptosis-related differentially expressed genes, the consensus clustering was used to classify glioma patients into two NI subgroups. Then, we revealed NI subgroup I were more sensitive to immunotherapy, particularly anti-PD1 therapy. This new NI-based classification may have prospective predictive factors for prognosis and guide physicians in prioritizing immunotherapy for potential responders.
坏死性凋亡是一种程序性坏死性细胞死亡形式，作为宿主防御某些病原体入侵的把关机制。以往的研究揭示了坏死性凋亡在肿瘤进展中的重要作用，并暗示了针对坏死性凋亡的新型疗法的潜力。然而，尚未对多组学数据进行全面分析，以更好地理解坏死性凋亡与肿瘤之间的关系。我们开发了坏死性凋亡指数（NI），以揭示坏死性凋亡在大多数癌症中的作用。NI不仅与多种肿瘤的临床特征相关，还能影响胶质瘤的药物敏感性。基于与坏死性凋亡相关的差异表达基因，采用一致性聚类将胶质瘤患者分为两个NI亚组。然后，我们发现NI亚组I对免疫疗法，尤其是抗PD1疗法更敏感。这种基于NI的新分类可能具有预后的前瞻性预测因素，并指导医生为潜在的反应者优先选择免疫疗法。
